News Upcoming Events 29th to 30th September – Formulation & Delivery Series US: Virtual 5th to 6th October – Bio Innovation Virtual Conference Press Releases 29th April 2020 – Upperton Invest £500K in their Tablet Formulation and Manufacturing Capabilities 10th December 2019 – Upperton is Launching an Enabling Technology Screening Protocol – UpperSolv™ 29th October 2019 – Upperton continues to invest in key equipment to support expansion of its solid dosage form capabilities and CDMO Services 17th September 2019 – Upperton Pharma Solutions Investment Increases Tabletting Capabilities 8th January 2019 – MHRA Inspection success for Nottingham’s Upperton Pharma Solutions Published Papers New GMP Manufacturing Processes to Obtain Thermostable HIV-1 gp41 Virosomes Under Solid Forms for Various Mucosal Vaccination Routes Upperton Articles 24th September 2020 – Key Considerations when Choosing a Device for Dry Powder Nasal Delivery 21st July 2020 – Considerations when Developing Dry Powder Formulations for Nasal Locally Delivered Drugs 9th June 2020 – Nasal Delivery: An Alternative Route 12th May 2020 – A Tablet Development Journey at Upperton 7th April 2020 – Stages of Tablet Development: Compression Equipment Used 10th March 2020 – Formulating Spray Dried Dispersions into Tablets 25th February 2020 – Applications and Techniques of Pharmaceutical Granulation 11th February 2020 – Tablets: A General Formulation Overview 28th January 2020 – Tablets: A General Overview 14th January 2020 – Oral Solid Dosage Forms Containing Amorphous Spray Dried Dispersions: Choices for First in Human Studies 19th December 2019 – Season’s Greeting and End of Year Review 12th December 2019 – Assessing Bioavailability Enabling Technologies using Upperton Pharma Solutions Screening Platform – UpperSolv™+ 1 2 3 › Can we help you? Contact Us
